Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

NCT02638428 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Pediatric Solid Tumor
Refractory Pediatric Solid Tumor
Relapsed Pediatric AML
Refractory Pediatric AML

Interventions

PROCEDURE: CancerSCAN™
DRUG: Ifosfamide
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Fludarabine
DRUG: Cytarabine
DRUG: Pazopanib
DRUG: Sorafenib
DRUG: Axitinib
DRUG: Crizotinib
DRUG: Dasatinib
DRUG: Erlotinib
DRUG: Everolimus
DRUG: Imatinib
DRUG: Ruxolitinib
DRUG: Vandetanib
DRUG: Vemurafenib
DRUG: Trastuzumab

Sponsor

Samsung Medical Center

Collaborators

[object Object]